Brain Volume and Diffusion Markers as Predictors of Disability and Short-Term Disease Evolution in Multiple Sclerosis

References

1. 1.↵
   1. Hauser SL,
   2. Oksenberg JR

   . The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006;52:61–76

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Anderson VM,
   2. Fox NC,
   3. Miller DH

   . Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging 2006;23:605–18

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Trapp BD,
   2. Ransohoff R,
   3. Rudick R

   . Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999;12:295–302

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Miller DH,
   2. Barkhof F,
   3. Frank JA,
   4. et al

   . Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676–95

   Abstract/FREE Full Text
5. 5.↵
   1. Rovaris M,
   2. Gass A,
   3. Bammer R,
   4. et al

   . Diffusion MRI in multiple sclerosis. Neurology 2005;65:1526–32

   Abstract/FREE Full Text
6. 6.↵
   1. Kalkers NF,
   2. Ameziane N,
   3. Bot JC,
   4. et al

   . Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002;59:1572–76

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Chard DT,
   2. Griffin CM,
   3. Parker GJ,
   4. et al

   . Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125:327–37

   Abstract/FREE Full Text
8. 8.↵
   1. De Stefano N,
   2. Matthews PM,
   3. Filippi M,
   4. et al

   . Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003;60:1157–62

   Abstract/FREE Full Text
9. 9.↵
   1. Zivadinov R,
   2. Sepcic J,
   3. Nasuelli D,
   4. et al

   . A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:773–80

   Abstract/FREE Full Text
10. 10.↵
    1. Sastre-Garriga J,
    2. Ingle GT,
    3. Chard DT,
    4. et al

    . Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. Neuroimage 2004;22:353–59

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Richert ND,
    2. Howard T,
    3. Frank JA,
    4. et al

    . Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis. Neurology 2006;66:551–56

    Abstract/FREE Full Text
12. 12.↵
    1. De Stefano N,
    2. Iannucci G,
    3. Sormani MP,
    4. et al

    . MR correlates of cerebral atrophy in patients with multiple sclerosis. J Neurol 2002;249:1072–77

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Bielekova B,
    2. Kadom N,
    3. Fisher E,
    4. et al

    . MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005;65:1071–76

    Abstract/FREE Full Text
14. 14.↵
    1. Fisher E,
    2. Rudick RA,
    3. Simon JH,
    4. et al

    . Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412–20

    Abstract/FREE Full Text
15. 15.↵
    1. Horakova D,
    2. Dwyer MG,
    3. Havrdova E,
    4. et al

    . Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. J Neurol Sci 2009;282:112–19

    CrossRefPubMed
16. 16.↵
    1. Ciccarelli O,
    2. Werring DJ,
    3. Wheeler-Kingshott CA,
    4. et al

    . Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology 2001;56:926–33

    Abstract/FREE Full Text
17. 17.↵
    1. Tortorella P,
    2. Rocca MA,
    3. Mezzapesa DM,
    4. et al

    . MRI quantification of gray and white matter damage in patients with early-onset multiple sclerosis. J Neurol 2006;253:903–07

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Cercignani M,
    2. Inglese M,
    3. Pagani E,
    4. et al

    . Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis. AJNR Am J Neuroradiol 2001;22:952–58

    Abstract/FREE Full Text
19. 19.↵
    1. Budde MD,
    2. Kim JH,
    3. Liang HF,
    4. et al

    . Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis. NMR Biomed 2008;21:589–97

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Phuttharak W,
    2. Galassi W,
    3. Laopaiboon V,
    4. et al

    . ADC measurements in various patterns of multiple sclerosis lesions. J Med Assoc Thai 2006;89:196–204

    PubMed
21. 21.↵
    1. Nusbaum AO,
    2. Lu D,
    3. Tang CY,
    4. et al

    . Quantitative diffusion measurements in focal multiple sclerosis lesions: correlations with appearance on TI-weighted MR images. AJR Am J Roentgenol 2000;175:821–25

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Vrenken H,
    2. Pouwels PJ,
    3. Geurts JJ,
    4. et al

    . Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration. J Magn Reson Imaging 2006;23:628–36

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Tavazzi E,
    2. Dwyer MG,
    3. Weinstock-Guttman B,
    4. et al

    . Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. Neuroimage 2007;36:746–54

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Wilson M,
    2. Morgan PS,
    3. Lin X,
    4. et al

    . Quantitative diffusion weighted magnetic resonance imaging, cerebral atrophy, and disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:318–22

    Abstract/FREE Full Text
25. 25.↵
    1. Oreja-Guevara C,
    2. Rovaris M,
    3. Iannucci G,
    4. et al

    . Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study. Arch Neurol 2005;62:578–84

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Rovaris M,
    2. Judica E,
    3. Gallo A,
    4. et al

    . Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain 2006;129:2628–34

    Abstract/FREE Full Text
27. 27.↵
    1. Fischer JS,
    2. Rudick RA,
    3. Cutter GR,
    4. et al

    . The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment—National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244–50

    Abstract/FREE Full Text
28. 28.↵
    1. Cassol E,
    2. Ranjeva JP,
    3. Ibarrola D,
    4. et al

    . Diffusion tensor imaging in multiple sclerosis: a tool for monitoring changes in normal-appearing white matter. Mult Scler 2004;10:188–96

    Abstract/FREE Full Text
29. 29.↵
    1. Gallo A,
    2. Rovaris M,
    3. Riva R,
    4. et al

    . Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis. Arch Neurol 2005;62:803–08

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Bermel RA,
    2. Puli SR,
    3. Rudick RA,
    4. et al

    . Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 2005;62:1371–76

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Tiberio M,
    2. Chard DT,
    3. Altmann DR,
    4. et al

    . Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 2005;64:1001–07

    Abstract/FREE Full Text
32. 32.↵
    1. Chard DT,
    2. Griffin CM,
    3. Rashid W,
    4. et al

    . Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Mult Scler 2004;10:387–91

    Abstract/FREE Full Text
33. 33.↵
    1. Paolillo A,
    2. Pozzilli C,
    3. Giugni E,
    4. et al

    . A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Eur J Neurol 2002;9:645–55

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Quarantelli M,
    2. Ciarmiello A,
    3. Morra VB,
    4. et al

    . Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. Neuroimage 2003;18:360–66

    CrossRefPubMed
35. 35.↵
    1. Lukas C,
    2. Minneboo A,
    3. de Groot V,
    4. et al

    . Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. J Neurol Neurosurg Psychiatry 2010;81:1351–56. Epub 2010 Sep 8

    Abstract/FREE Full Text
36. 36.↵
    1. Mesaros S,
    2. Rocca MA,
    3. Sormani MP,
    4. et al

    . Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS: a large scale, short-term follow-up study. J Neurol 2008;255:1378–83

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Rovaris M,
    2. Gallo A,
    3. Valsasina P,
    4. et al

    . Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. Neuroimage 2005;24:1139–46

    CrossRefPubMedWeb of Science
38. 38.↵
    1. McDonald WI,
    2. Compston A,
    3. Edan G,
    4. et al

    . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121–27

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Garaci FG,
    2. Colangelo V,
    3. Ludovici A,
    4. et al

    . A diffusion longitudinal MR imaging study in normal-appearing white matter in untreated relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2007;28:475–78

    Abstract/FREE Full Text
40. 40.↵
    1. Kurtzke JF

    . Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52

    Abstract/FREE Full Text
41. 41.↵
    1. Chabriat H,
    2. Pappata S,
    3. Poupon C,
    4. et al

    . Clinical severity in CADASIL related to ultrastructural damage in white matter: in vivo study with diffusion tensor MRI. Stroke 1999;30:2637–43

    Abstract/FREE Full Text
42. 42.↵
    1. Chard DT,
    2. Parker GJ,
    3. Griffin CM,
    4. et al

    . The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. J Magn Reson Imaging 2002;15:259–67

    CrossRefPubMedWeb of Science
43. 43.↵
    1. Smith SM,
    2. Zhang Y,
    3. Jenkinson M,
    4. et al

    . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Van Leemput K,
    2. Maes F,
    3. Vandermeulen D,
    4. et al

    . Automated segmentation of multiple sclerosis lesions by model outlier detection. IEEE Trans Med Imaging 2001;20:677–88

    CrossRefPubMedWeb of Science
45. 45.↵
    1. Cercignani M,
    2. Bozzali M,
    3. Iannucci G,
    4. et al

    . Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:311–17

    Abstract/FREE Full Text
46. 46.↵
    1. Griffin CM,
    2. Chard DT,
    3. Ciccarelli O,
    4. et al

    . Diffusion tensor imaging in early relapsing-remitting multiple sclerosis. Mult Scler 2001;7:290–97

    Abstract/FREE Full Text
47. 47.↵
    1. van Waesberghe JH,
    2. Kamphorst W,
    3. De Groot CJ,
    4. et al

    . Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999;46:747–54

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Rudick RA,
    2. Fisher E,
    3. Lee JC,
    4. et al

    . Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698–704

    Abstract/FREE Full Text
49. 49.↵
    1. Guttmann CR,
    2. Meier DS,
    3. Holland CM

    . Can MRI reveal phenotypes of multiple sclerosis? Magn Reson Imaging 2006;24:475–81

    CrossRefPubMed
50. 50.↵
    1. Simon JH,
    2. Jacobs LD,
    3. Campion MK,
    4. et al

    . A longitudinal study of brain atrophy in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1999;53:139–48

    Abstract/FREE Full Text
51. 51.↵
    1. Kalkers NF,
    2. Vrenken H,
    3. Uitdehaag BM,
    4. et al

    . Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue. Mult Scler 2002;8:410–14

    Abstract/FREE Full Text
52. 52.↵
    1. Kalkers NF,
    2. Bergers E,
    3. Castelijns JA,
    4. et al

    . Optimizing the association between disability and biological markers in MS. Neurology 2001;57:1253–58

    Abstract/FREE Full Text
53. 53.↵
    1. Hildebrandt H,
    2. Hahn HK,
    3. Kraus JA,
    4. et al

    . Memory performance in multiple sclerosis patients correlates with central brain atrophy. Mult Scler 2006;12:428–36

    Abstract/FREE Full Text
54. 54.↵
    1. Lazeron RH,
    2. Boringa JB,
    3. Schouten M,
    4. et al

    . Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. Mult Scler 2005;11:524–31

    Abstract/FREE Full Text
55. 55.↵
    1. Kalkers NF,
    2. de Groot V,
    3. Lazeron RH,
    4. et al

    . MS functional composite: relation to disease phenotype and disability strata. Neurology 2000;54:1233–39

    Abstract/FREE Full Text
56. 56.↵
    1. Schmierer K,
    2. Altmann DR,
    3. Kassim N,
    4. et al

    . Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study. Mult Scler 2004;10:182–87

    Abstract/FREE Full Text
57. 57.↵
    1. Molyneux PD,
    2. Kappos L,
    3. Polman C,
    4. et al

    . The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis: European Study Group on Interferon Beta-1b in Secondary Progressive Multiple Sclerosis. Brain 2000;123 (pt 11): 2256–63

    Abstract/FREE Full Text
58. 58.↵
    1. Rovaris M,
    2. Confavreux C,
    3. Furlan R,
    4. et al

    . Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006;5:343–54

    CrossRefPubMedWeb of Science
59. 59.↵
    1. Dichgans M,
    2. Putz B,
    3. Boos D,
    4. et al

    . Role of subvoxel free fluid on diffusion parameters in brain tissue with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and its correlation with physical disability: histogram analysis of standard and fluid-attenuated MR diffusion. AJNR Am J Neuroradiol 2003;24:1083–89

    Abstract/FREE Full Text